Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Moyamoya Disease Companies

Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing of certain arteries at the base of the brain. Companies involved in the field of Moyamoya disease may focus on various aspects, including research, diagnostics, and therapeutic interventions.

Moyamoya Disease Key Companies

Latest Moyamoya Disease Companies Update

Merck & Co. Received US FDA priority review for sotatercept, an experimental therapy for Moyamoya disease and other progressive blood vessel disorders.Target action date for the review is March 26, 2024. Approval would solidify Merck's position in the Moyamoya disease market.

Valenta Pharmaceuticals Launched Ethoxidol, a new generation antioxidant for treating chronic brain ischemia (cerebrovascular insufficiency) associated with Moyamoya disease.Ethoxidol's unique mechanism of action has the potential to improve outcomes for patients with Moyamoya disease.

Abbott Laboratories Continues to market its Xience V balloon expandable stent system for revascularization procedures in Moyamoya disease.Xience V stents are designed to minimize re-narrowing of the artery after angioplasty, a common complication in Moyamoya disease patients.

Boston Scientific Corporation Offers its Solitaire™ FR reperfusion device for minimally invasive treatment of Moyamoya disease-related ischemic strokes.The Solitaire device is effective in removing blood clots and restoring blood flow to the brain.

List of Moyamoya Disease Key Companies in the Market

Abbott Laboratories

Boston Scientific Corporation

Cephalon Inc.

Cordis Corporation

Eisai Co. Ltd

GE Healthcare

Genentech Inc.

GlaxoSmithKline PLC.

Johnson & Johnson

Koninklijke Philips N.V.

Medtronic plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

Siemens

Stryker

Sunovion Pharmaceuticals Inc.

UCB Pharma Ltd.

Valeant Pharmaceuticals International Inc

Moyamoya Disease Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.